Publication of positive results is almost always a highly positive trigger for a pharmaceutical or biotech stock, and that is what IFRX stock experienced this morning. In a new development today, InflaRx NV (NASDAQ:IFRX) announced highly positive results from its Phase B clinical trial, called SHINE, of its lead candidate.
Bullish ReactionThe lead candidate in question is IFX-1, which is supposed to be used to treat patients suffering from hidradenitis suppurativa, a type of inflammatory skin condition. It goes without saying that this is a significant development for this nano-cap company, and the market has ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.